Von dem Buch Clinical Benefits of Leukodepleted Blood Products haben wir 3 gleiche oder sehr ähnliche Ausgaben identifiziert!

Falls Sie nur an einem bestimmten Exempar interessiert sind, können Sie aus der folgenden Liste jenes wählen, an dem Sie interessiert sind:

Clinical Benefits of Leukodepleted Blood Products100%: Bjarne S. Jensen: Clinical Benefits of Leukodepleted Blood Products (ISBN: 9783662265383) Springer Berlin Heidelberg, in Englisch, auch als eBook.
Nur diese Ausgabe anzeigen…
Clinical Benefits of Leukodepleted Blood Products (Medical Intelligence Unit)100%: J. (American Red Cross, Norfolk, Virginia, Usa) Sweeney: Clinical Benefits of Leukodepleted Blood Products (Medical Intelligence Unit) (ISBN: 9781570591228) Springer, in Englisch, Taschenbuch.
Nur diese Ausgabe anzeigen…
Clinical Benefits of Leukodepleted Blood Products (Medical Intelligence Unit)100%: Herausgeber: Joseph Sweeney, Herausgeber: Andrew Heaton: Clinical Benefits of Leukodepleted Blood Products (Medical Intelligence Unit) (ISBN: 9783540588931) 1995, Erstausgabe, in Englisch, Broschiert.
Nur diese Ausgabe anzeigen…

Clinical Benefits of Leukodepleted Blood Products - 15 Angebote vergleichen

Bester Preis: Fr. 61.36 ( 62.88)¹ (vom 04.02.2018)
1
9783540588931 - n/a: Clinical Benefits of Leukodepleted Blood Products (Medical Intelligence Unit)
Symbolbild
n/a

Clinical Benefits of Leukodepleted Blood Products (Medical Intelligence Unit) (1995)

Lieferung erfolgt aus/von: Vereinigte Staaten von Amerika DE FE

ISBN: 9783540588931 bzw. 3540588930, in Deutsch, Springer, Berlin/Heidelberg, Deutschland, Erstausgabe.

Fr. 33.68 ( 34.51)¹
versandkostenfrei, unverbindlich
Lieferung aus: Vereinigte Staaten von Amerika, Versandkostenfrei.
Von Händler/Antiquariat, Better World Books [51315977], Mishawaka, IN, U.S.A.
Shows some signs of wear, and may have some markings on the inside. 100% Money Back Guarantee. Shipped to over one million happy customers. Your purchase benefits world literacy!
2
9781570591228 - Editor: Joseph Sweeney: Clinical Benefits of Leukodepleted Blood Products (Medical Intelligence Unit)
Editor: Joseph Sweeney

Clinical Benefits of Leukodepleted Blood Products (Medical Intelligence Unit) (1995)

Lieferung erfolgt aus/von: Vereinigte Staaten von Amerika EN PB NW

ISBN: 9781570591228 bzw. 1570591229, in Englisch, 198 Seiten, Springer, Taschenbuch, neu.

Fr. 63.83 ($ 73.19)¹ + Versand: Fr. 3.48 ($ 3.99)¹ = Fr. 67.32 ($ 77.18)¹
unverbindlich
Lieferung aus: Vereinigte Staaten von Amerika, Usually ships in 1-2 business days.
Von Händler/Antiquariat, affordable2015.
Joseph Sweeney, Andrew Heaton he presence of allogeneic leukocytes in blood products received little T attention until the mid-1950s when these "passenger" cells were im­ plicated in the etiology of febrile transfusion reactions, and early strate­ gies based on centrifugation were developed to effect their removal. In recent decades and, particularly in the past five years, there has been an accumulation of literature implicating leukocytes in a wide variety of undesirable reactions to blood transfusion. White cells are the least numerous of the cellular elements in blood and ratios of white cells to platelets and white cells to red cells are ap­ proximately 1:15 to 1:1000 respectively. This ratio is maintained in whole blood, but may be altered slightly in the process of component prepara­ tion. Any production or processing step which intentionally decreases this ratio will result in a product which can be described as white cell depleted. It has, however, become more common to define the outcome as a residual white cell content, rather than a decrease in cellular ratios, although the latter makes more sense on theoretical grounds, since deple­ tion of white cells needs to be put in the context of any unintentional loss of red cells or platelets. The end result of this intentional processing step, therefore, is generally expressed as the residual absolute number of white cells or as the degree of difference in white cell content, the latter expressed as either a percentage change or as a logarithmic reduction. Paperback, Ausgabe: Softcover reprint of the original 1st ed. 1995, Label: Springer, Springer, Produktgruppe: Book, Publiziert: 1995-01-01, Studio: Springer, Verkaufsrang: 12379822.
3
9781570591228 - Editor: Joseph Sweeney: Clinical Benefits of Leukodepleted Blood Products (Medical Intelligence Unit)
Editor: Joseph Sweeney

Clinical Benefits of Leukodepleted Blood Products (Medical Intelligence Unit) (1995)

Lieferung erfolgt aus/von: Vereinigte Staaten von Amerika EN PB US

ISBN: 9781570591228 bzw. 1570591229, in Englisch, 198 Seiten, Springer, Taschenbuch, gebraucht.

Fr. 20.87 ($ 23.93)¹ + Versand: Fr. 3.48 ($ 3.99)¹ = Fr. 24.36 ($ 27.92)¹
unverbindlich
Lieferung aus: Vereinigte Staaten von Amerika, Usually ships in 1-2 business days.
Von Händler/Antiquariat, Roadkill Books.
Joseph Sweeney, Andrew Heaton he presence of allogeneic leukocytes in blood products received little T attention until the mid-1950s when these "passenger" cells were im­ plicated in the etiology of febrile transfusion reactions, and early strate­ gies based on centrifugation were developed to effect their removal. In recent decades and, particularly in the past five years, there has been an accumulation of literature implicating leukocytes in a wide variety of undesirable reactions to blood transfusion. White cells are the least numerous of the cellular elements in blood and ratios of white cells to platelets and white cells to red cells are ap­ proximately 1:15 to 1:1000 respectively. This ratio is maintained in whole blood, but may be altered slightly in the process of component prepara­ tion. Any production or processing step which intentionally decreases this ratio will result in a product which can be described as white cell depleted. It has, however, become more common to define the outcome as a residual white cell content, rather than a decrease in cellular ratios, although the latter makes more sense on theoretical grounds, since deple­ tion of white cells needs to be put in the context of any unintentional loss of red cells or platelets. The end result of this intentional processing step, therefore, is generally expressed as the residual absolute number of white cells or as the degree of difference in white cell content, the latter expressed as either a percentage change or as a logarithmic reduction. Paperback, Ausgabe: Softcover reprint of the original 1st ed. 1995, Label: Springer, Springer, Produktgruppe: Book, Publiziert: 1995-01-01, Studio: Springer, Verkaufsrang: 12379822.
4
9783662265383 - Alfred Vogt: Clinical Benefits of Leukodepleted Blood Products
Alfred Vogt

Clinical Benefits of Leukodepleted Blood Products

Lieferung erfolgt aus/von: Vereinigtes Königreich Grossbritannien und Nordirland EN NW EB DL

ISBN: 9783662265383 bzw. 3662265389, in Englisch, Springer Berlin Heidelberg, neu, E-Book, elektronischer Download.

Fr. 85.52 (£ 76.08)¹ + Versand: Fr. 7.86 (£ 6.99)¹ = Fr. 93.37 (£ 83.07)¹
unverbindlich
Lieferung aus: Vereinigtes Königreich Grossbritannien und Nordirland, Despatched same working day before 3pm.
Joseph Sweeney, Andrew Heaton he presence of allogeneic leukocytes in blood products received little T attention until the mid-1950s when these "passenger" cells were im- plicated in the etiology of febrile transfusion reactions, and early strate- gies based on centrifugation were developed to effect their removal.In recent decades and, particularly in the past five years, there has been an accumulation of literature implicating leukocytes in a wide variety of undesirable reactions to blood transfusion.White cells are the least numerous of the cellular elements in blood and ratios of white cells to platelets and white cells to red cells are ap- proximately 1:15 to 1:1000 respectively.This ratio is maintained in whole blood, but may be altered slightly in the process of component prepara- tion.Any production or processing step which intentionally decreases this ratio will result in a product which can be described as white cell depleted.It has, however, become more common to define the outcome as a residual white cell content, rather than a decrease in cellular ratios, although the latter makes more sense on theoretical grounds, since deple- tion of white cells needs to be put in the context of any unintentional loss of red cells or platelets.The end result of this intentional processing step, therefore, is generally expressed as the residual absolute number of white cells or as the degree of difference in white cell content, the latter expressed as either a percentage change or as a logarithmic reduction.
5
9781570591228 - J. (American Red Cross, Norfolk, Virginia, Usa) Sweeney: Clinical Benefits of Leukodepleted Blood Products
J. (American Red Cross, Norfolk, Virginia, Usa) Sweeney

Clinical Benefits of Leukodepleted Blood Products (1994)

Lieferung erfolgt aus/von: Niederlande EN PB NW

ISBN: 9781570591228 bzw. 1570591229, in Englisch, Springer, Taschenbuch, neu.

Fr. 84.36 ( 86.44)¹
unverbindlich
Lieferung aus: Niederlande, 3-4 weken.
bol.com.
Provides a state-of-the-art description of the current status of leukodepleted blood products. Advances in technology, particularly filtration, have achieved great success in the selective removal of these white cells, and this book examines the benefits of such blood products. Productinformatie:Taal: Engels;Afmetingen: 0x0x0 mm;Gewicht: 0,00 gram;ISBN10: 1570591229;ISBN13: 9781570591228; Engels | Paperback | 1994.
6
9781570591228 - Springer: Clinical Benefits of Leukodepleted Blood Products
Springer

Clinical Benefits of Leukodepleted Blood Products

Lieferung erfolgt aus/von: Deutschland EN NW

ISBN: 9781570591228 bzw. 1570591229, in Englisch, neu.

Fr. 90.86 ( 93.10)¹
unverbindlich
Lieferung aus: Deutschland, zzgl. Versandkosten, Versandfertig in 5 - 7 Tagen.
Clinical Benefits of Leukodepleted Blood Products, Joseph Sweeney, Andrew Heaton he presence of allogeneic leukocytes in blood products received little T attention until the mid-1950s when these "passenger" cells were im plicated in the etiology of febrile transfusion reactions, and early strate gies based on centrifugation were developed to effect their removal. In recent decades and, particularly in the past five years, there has been an accumulation of literature implicating leukocytes in a wide variety of undesirable reactions to blood transfusion. White cells are the least numerous of the cellular elements in blood and ratios of white cells to platelets and white cells to red cells are ap proximately 1:15 to 1:1000 respectively. This ratio is maintained in whole blood, but may be altered slightly in the process of component prepara tion. Any production or processing step which intentionally decreases this ratio will result in a product which can be described as white cell depleted. It has, however, become more common to define the outcome as a residual white cell content, rather than a decrease in cellular ratios, although the latter makes more sense on theoretical grounds, since deple tion of white cells needs to be put in the context of any unintentional loss of red cells or platelets. The end result of this intentional processing step, therefore, is generally expressed as the residual absolute number of white cells or as the degree of difference in white cell content, the latter expressed as either a percentage change or as a logarithmic reduction.
7
9783540588931 - n/a: Clinical Benefits of Leukodepleted Blood Products (Medical Intelligence Unit)
Symbolbild
n/a

Clinical Benefits of Leukodepleted Blood Products (Medical Intelligence Unit) (1995)

Lieferung erfolgt aus/von: Vereinigte Staaten von Amerika DE US FE

ISBN: 9783540588931 bzw. 3540588930, in Deutsch, Springer, gebraucht, Erstausgabe.

Fr. 203.56 ( 208.59)¹
versandkostenfrei, unverbindlich
Lieferung aus: Vereinigte Staaten von Amerika, Versandkostenfrei.
Von Händler/Antiquariat, Better World Books [51315977], Mishawaka, IN, U.S.A.
Shows some signs of wear, and may have some markings on the inside.
8
9783540588931 - a cura di: Joseph Sweeney, a cura di: Andrew Heaton: Clinical Benefits of Leukodepleted Blood Products
Symbolbild
a cura di: Joseph Sweeney, a cura di: Andrew Heaton

Clinical Benefits of Leukodepleted Blood Products (1995)

Lieferung erfolgt aus/von: Italien EN US

ISBN: 9783540588931 bzw. 3540588930, in Englisch, 208 Seiten, Springer-Verlag Berlin and Heidelberg GmbH & Co. K, gebraucht.

Fr. 53.86 ( 55.19)¹
unverbindlich
Lieferung aus: Italien, Generalmente spedito in 1-2 giorni lavorativi.
Von Händler/Antiquariat, FastMedia "navi da Stati USA"
Die Beschreibung dieses Angebotes ist von geringer Qualität oder in einer Fremdsprache. Trotzdem anzeigen
9
9783540588931 - Redactor: Joseph Sweeney, Redactor: Andrew Heaton: Clinical Benefits of Leukodepleted Blood Products (Medical Intelligence Unit)
Symbolbild
Redactor: Joseph Sweeney, Redactor: Andrew Heaton

Clinical Benefits of Leukodepleted Blood Products (Medical Intelligence Unit) (1995)

Lieferung erfolgt aus/von: Spanien EN US

ISBN: 9783540588931 bzw. 3540588930, in Englisch, 208 Seiten, Springer-Verlag Berlin and Heidelberg GmbH & Co. K, gebraucht.

Fr. 53.86 ( 55.19)¹
unverbindlich
Lieferung aus: Spanien, Normalmente se envía en el plazo de 1-2 días laborable.
Von Händler/Antiquariat, FastMedia "Despachos de USA"
Die Beschreibung dieses Angebotes ist von geringer Qualität oder in einer Fremdsprache. Trotzdem anzeigen
10
9783540588931 - n/a: Clinical Benefits of Leukodepleted Blood Products (Medical Intelligence Unit)
Symbolbild
n/a

Clinical Benefits of Leukodepleted Blood Products (Medical Intelligence Unit) (1995)

Lieferung erfolgt aus/von: Vereinigte Staaten von Amerika DE US FE

ISBN: 9783540588931 bzw. 3540588930, in Deutsch, Springer, gebraucht, Erstausgabe.

Fr. 229.42 ( 235.09)¹
versandkostenfrei, unverbindlich
Lieferung aus: Vereinigte Staaten von Amerika, Versandkostenfrei.
Von Händler/Antiquariat, Better World Books [51315977], Mishawaka, IN, U.S.A.
Great condition for a used book! Minimal wear.
Lade…